AbbVie Bolsters Immunology Pipeline with $10.9 Billion Apogee Acquisition
The acquisition would add a longer-acting alternative to Dupixent for inflammatory diseases.
/ 238 items
#XY Event-Driven Stocks↓
MoonLake’s Sonelokimab Achieves High Response Rates in HS After 12 Months
Sonelokimab shows strong 1-year results in HS, with many patients seeing clear skin, less pain, and better quality of life, with good safety.
Pfizer Announces Departure of CFO Dave Denton, Names Interim Successor
Cecile Guegan named Interim CFO as the company reaffirms its 2026 guidance.
Novocure Stock Plunges After Phase 3 TRIDENT Study Fails to Meet Primary Goal
Novocure’s Phase 3 TRIDENT trial failed to show survival benefit from earlier TTFields initiation in newly diagnosed glioblastoma.
Biogen Acquires RayThera for Up to $1 Billion to Expand Immunology Pipeline
The deal adds multiple early-stage small-molecule immunology assets to Biogen’s pipeline, with the lead candidate entering Phase 1 in Q3 2026.
FDA Clears Path for AXPAXLI: Ocular Therapeutix Targets Late 2026 NDA Submission
Ocular Therapeutix has reached alignment with the FDA to submit the AXPAXLI NDA for wet AMD in Q4 2026, based on SOL-1 data and interim SOL-R safety results. Topline SOL-R data now expected in Q1 2028.